CN101175489A - 用17-aag或17-ag或其前药治疗多发性骨髓瘤的方法 - Google Patents

用17-aag或17-ag或其前药治疗多发性骨髓瘤的方法 Download PDF

Info

Publication number
CN101175489A
CN101175489A CNA2006800140087A CN200680014008A CN101175489A CN 101175489 A CN101175489 A CN 101175489A CN A2006800140087 A CNA2006800140087 A CN A2006800140087A CN 200680014008 A CN200680014008 A CN 200680014008A CN 101175489 A CN101175489 A CN 101175489A
Authority
CN
China
Prior art keywords
aag
dose
administered
cmax
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800140087A
Other languages
English (en)
Chinese (zh)
Inventor
R·约翰逊
A·汉纳
G·克罗普
周憶清
J·谢里尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kosan Biosciences Inc
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of CN101175489A publication Critical patent/CN101175489A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2006800140087A 2005-04-29 2006-04-26 用17-aag或17-ag或其前药治疗多发性骨髓瘤的方法 Pending CN101175489A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US67644905P 2005-04-29 2005-04-29
US60/676,449 2005-04-29
US68094405P 2005-05-12 2005-05-12
US60/680,944 2005-05-12
US72170705P 2005-09-28 2005-09-28
US60/721,707 2005-09-28
US74920005P 2005-12-09 2005-12-09
US60/749,200 2005-12-09

Publications (1)

Publication Number Publication Date
CN101175489A true CN101175489A (zh) 2008-05-07

Family

ID=37308498

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800140087A Pending CN101175489A (zh) 2005-04-29 2006-04-26 用17-aag或17-ag或其前药治疗多发性骨髓瘤的方法

Country Status (12)

Country Link
US (1) US7691392B2 (enExample)
EP (1) EP1874296A4 (enExample)
JP (1) JP2008539265A (enExample)
KR (1) KR20080000682A (enExample)
CN (1) CN101175489A (enExample)
AU (1) AU2006242540A1 (enExample)
BR (1) BRPI0610411A2 (enExample)
CA (1) CA2604473A1 (enExample)
IL (1) IL186292A0 (enExample)
MX (1) MX2007013494A (enExample)
RU (1) RU2007144195A (enExample)
WO (1) WO2006118953A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110917190A (zh) * 2019-11-29 2020-03-27 中国人民解放军军事科学院军事医学研究院 一种抑制阿片类镇痛药物不良反应的制剂及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
ATE194767T1 (de) * 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
WO1994026254A1 (en) 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
AU3415295A (en) * 1994-09-22 1996-04-09 Glenayre Electronics, Inc Synchronized paging system
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6682758B1 (en) * 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
WO2000071163A1 (en) 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9918429D0 (en) 1999-08-04 1999-10-06 Novartis Ag Organic compounds
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
CA2481683A1 (en) 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
WO2004000229A2 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
JP2006514994A (ja) 2003-03-13 2006-05-18 コンフォーマ・セラピューティクス・コーポレイション 長鎖および中鎖トリグリセリドを有する医薬製剤
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7282493B2 (en) * 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
WO2005115431A2 (en) 2004-05-24 2005-12-08 Adonia Papathanassiu Methods for inhibiting proteasome and heat shock protein 90
WO2006034147A2 (en) 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
JP2008531708A (ja) 2005-02-28 2008-08-14 コーザン バイオサイエンシス インコーポレイテッド １７−アリルアミノ−１７−デメトキシゲルダナマイシンを含有する医薬製剤
CA2601706C (en) * 2005-03-22 2016-09-20 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
EP1874297A4 (en) * 2005-04-29 2009-04-22 Kosan Biosciences Inc METHOD OF TREATING MULTIPLE MYELOMES USING 17AGENE OR 17-AG OR A PRODRUG OR ALL IN COMBINATION WITH A PROTEASOMIC INHIBITOR

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110917190A (zh) * 2019-11-29 2020-03-27 中国人民解放军军事科学院军事医学研究院 一种抑制阿片类镇痛药物不良反应的制剂及其应用
CN110917190B (zh) * 2019-11-29 2022-12-23 中国人民解放军军事科学院军事医学研究院 一种抑制阿片类镇痛药物不良反应的制剂及其应用

Also Published As

Publication number Publication date
RU2007144195A (ru) 2009-06-10
EP1874296A2 (en) 2008-01-09
IL186292A0 (en) 2008-08-07
MX2007013494A (es) 2008-01-24
WO2006118953A2 (en) 2006-11-09
WO2006118953A3 (en) 2007-12-06
JP2008539265A (ja) 2008-11-13
US7691392B2 (en) 2010-04-06
KR20080000682A (ko) 2008-01-02
BRPI0610411A2 (pt) 2010-06-22
EP1874296A4 (en) 2010-06-30
AU2006242540A1 (en) 2006-11-09
US20060252739A1 (en) 2006-11-09
CA2604473A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
JP2020525427A (ja) 癌を処置するための方法
US20060252740A1 (en) Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
CN109562177A (zh) Hdac抑制剂和pd-1抑制剂的组合疗法
CN109640985A (zh) Hdac抑制剂和pd-l1抑制剂的组合疗法
US12447150B2 (en) Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy
KR20200014298A (ko) Her2 양성 암의 치료
KR20210018253A (ko) 면역 체크포인트 저해약의 유효성 판정 바이오마커
JP2021523190A (ja) 腺様嚢胞癌を治療するためのビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物
BRPI0617949A2 (pt) método de tratamento de cáncer de mama usando 17-aag ou 17-ag ou um pró-fármaco de qualquer um dos mesmos em combinação com um inibidor de her2
JP2016515625A (ja) 増殖性疾患を治療するための併用療法
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
CN101175489A (zh) 用17-aag或17-ag或其前药治疗多发性骨髓瘤的方法
CN101166526A (zh) 用17-aag或17-ag或其前药与蛋白酶体抑制剂联合治疗多发性骨髓瘤的方法
TW202517679A (zh) 以抗ｉｌｔ２抗體治療癌症
WO2025059579A1 (en) Methods of treating mat2a related diseases
EP4638503A1 (en) Combination therapy for lung cancer
EP4347037A1 (en) Methods of treating multiple myeloma using combination therapy
WO2023230554A1 (en) Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
MX2008005467A (en) Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor
TW202206103A (zh) Ｃｌｌ的治療

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080507